| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ceanothic acid does not have a well-defined specific molecular target. As a triterpenoid, it is thought to exert its effects through multiple mechanisms, including induction of apoptosis, disruption of mitochondrial function, and modulation of signaling pathways. It is useful for probing triterpenoid-driven cytotoxicity and structure-activity relationships within the betulinic acid family.
|
|---|---|
| ln Vitro |
In vitro, Ceanothic acid inhibits OVCAR-3, HeLa, and FS-5 cells with cell survival rates of 68%, 65%, and 81%, respectively. It demonstrates cytotoxic activity against various cancer cell lines. The compound is a ring-A homologue of betulinic acid, suggesting similar mechanisms of action.
|
| ln Vivo |
In vivo, Ceanothic acid has been studied for its potential antitumor effects. As a natural triterpenoid, it may exhibit anticancer activity in animal models. Specific in vivo data including efficacy in tumor models and toxicity profiles are limited in the published literature.
|
| Enzyme Assay |
In vitro cytotoxicity assays for Ceanothic acid typically use cancer cell lines such as OVCAR-3 (ovarian), HeLa (cervical), and FS-5 (fibrosarcoma). Cells are seeded in 96-well plates and treated with varying concentrations of Ceanothic acid for 48-72 hours. Cell viability is measured using MTT, CCK-8, or SRB assays. IC50 values or percentage cell survival are calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for Ceanothic acid typically involve assessment of apoptosis, cell cycle distribution, and mitochondrial membrane potential. Cells are treated with the compound at various concentrations, and apoptosis is measured by Annexin V/PI staining and flow cytometry. Cell cycle analysis is performed by propidium iodide staining. Mitochondrial membrane potential is measured using JC-1 dye.
|
| Animal Protocol |
In vivo animal studies for antitumor efficacy would typically use xenograft tumor models in immunocompromised mice. Animals would be implanted with cancer cells and treated with Ceanothic acid via oral or intraperitoneal administration. Tumor growth would be monitored by caliper measurement, and tumor weight would be determined at study termination. However, specific in vivo protocols for Ceanothic acid are limited.
|
| ADME/Pharmacokinetics |
Ceanothic acid is a natural pentacyclic triterpenoid with physicochemical properties typical of lipophilic natural products. It has limited aqueous solubility and is typically formulated in DMSO or other organic solvents for in vitro studies. Detailed PK parameters such as half-life, bioavailability, and clearance are not extensively published for this compound.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of Ceanothic acid would typically include acute toxicity in rodents and cytotoxicity assays in cell lines. As a natural triterpenoid, it is generally considered to have moderate toxicity. Comprehensive toxicity data are not extensively published, as the compound is primarily used as a research tool.
|
| References | |
| Additional Infomation |
According to reports, jujubes, Qinghai clams, and other organisms with available data contain cetearic acid.
Ceanothic acid (Emmolic acid) is a pentacyclic triterpenoid and a ring-A homologue of betulinic acid. It inhibits OVCAR-3, HeLa, and FS-5 cells with cell survival rates of 68%, 65%, and 81%, respectively. The compound is used for probing triterpenoid-driven cytotoxicity and is available for research use only. |
| Molecular Formula |
C30H46O5
|
|---|---|
| Molecular Weight |
486.68324
|
| Exact Mass |
486.334
|
| CAS # |
21302-79-4
|
| PubChem CID |
161352
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
609.0±55.0 °C at 760 mmHg
|
| Melting Point |
356-357°
|
| Flash Point |
336.1±28.0 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
1.549
|
| LogP |
7.24
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
35
|
| Complexity |
970
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4([C@H]([C@@H](C5(C)C)O)C(=O)O)C)C)C(=O)O
|
| InChi Key |
WLCHQSHZHFLMJH-VILVJDKQSA-N
|
| InChi Code |
InChI=1S/C30H46O5/c1-16(2)17-10-13-30(25(34)35)15-14-27(5)18(21(17)30)8-9-20-28(27,6)12-11-19-26(3,4)23(31)22(24(32)33)29(19,20)7/h17-23,31H,1,8-15H2,2-7H3,(H,32,33)(H,34,35)/t17-,18+,19-,20-,21+,22+,23-,27+,28+,29-,30-/m0/s1
|
| Chemical Name |
(1R,2R,5S,8R,9R,10R,13R,14R,15R,16S,18R)-16-hydroxy-1,2,14,17,17-pentamethyl-8-prop-1-en-2-ylpentacyclo[11.7.0.02,10.05,9.014,18]icosane-5,15-dicarboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0547 mL | 10.2737 mL | 20.5474 mL | |
| 5 mM | 0.4109 mL | 2.0547 mL | 4.1095 mL | |
| 10 mM | 0.2055 mL | 1.0274 mL | 2.0547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
